Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
Launched by M.D. ANDERSON CANCER CENTER · Jan 16, 2025
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to help older men with localized prostate cancer make informed decisions about their ongoing care, particularly when it comes to reducing the frequency of surveillance tests like biopsies and imaging. Sometimes, men with prostate cancer do not need aggressive treatment, and this study aims to provide them and their caregivers with better tools and information to decide if and when they can safely decrease their testing.
To participate in this study, men must be 65 years or older, have localized prostate cancer, and not be undergoing any curative treatment for it. Caregivers, such as family members or close friends, who help in the patient's care and are at least 18 years old can also join. Participants will receive educational support to help them understand their options and feel more confident in making decisions with their healthcare providers. This study is currently recruiting participants, so it’s a great opportunity for eligible men and their caregivers to get involved.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- Patients:
- • 1. Males aged 65 or older
- • 2. Diagnosis of localized prostate cancer
- • 3. Have not received curative intent treatment for their prostate cancer
- • 4. Fluent in English
- Care partners/caregivers:
- • 1. Aged 18 or older
- • 2. Fluent in English
- • 3. Involved with the care of an eligible patient (i.e. partner, close friend, family member, companion)
- Exclusion Criteria:
- • Patients
- • 1. Currently receiving treatment for another cancer (primary or recurrence)
- • Care partners/caregivers
- • 1. None
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Lisa Lowenstein, MD
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported